Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
Multiple myeloma remains an incurable disease although the prognosis has been improved by novel therapeutics and agents recently. Relapse occurs in the majority of patients and becomes fatal finally. Immunotherapy might be a powerful intervention to maintain a long-lasting control of minimal residua...
Saved in:
Main Authors: | Lu Zhang, Marlies Götz, Susanne Hofmann, Jochen Greiner |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2012/820394 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy
by: Dewen Zhan, et al.
Published: (2025-01-01) -
A new paradigm for cancer immunotherapy: targeting immunogenic cell death-related noncoding RNA
by: Guojuan Sun, et al.
Published: (2025-01-01) -
Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01) -
Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer
by: Esen Yonca Bassoy, et al.
Published: (2025-12-01) -
Silver nanoparticle induced immunogenic cell death can improve immunotherapy
by: Ara Sargsian, et al.
Published: (2024-11-01)